Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by JOSE ANTONIO KARAM and NIZAR M TANNIR.
JOSE ANTONIO KARAM
Connection Strength
5.178
NIZAR M TANNIR
  1. Re: Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. J Urol. 2013 Nov; 190(5):1710.
    View in: PubMed
    Score: 0.459
  2. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol. 2011 Feb; 185(2):439-44.
    View in: PubMed
    Score: 0.383
  3. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun. 2023 05 10; 14(1):2684.
    View in: PubMed
    Score: 0.226
  4. Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. Urol Oncol. 2021 12; 39(12):837.e9-837.e17.
    View in: PubMed
    Score: 0.202
  5. Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urol Oncol. 2021 11; 39(11):790.e17-790.e23.
    View in: PubMed
    Score: 0.200
  6. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. 2021 02; 39(2):134.e9-134.e16.
    View in: PubMed
    Score: 0.190
  7. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology. Curr Opin Urol. 2019 09; 29(5):521-525.
    View in: PubMed
    Score: 0.175
  8. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. Eur Urol Oncol. 2020 10; 3(5):687-694.
    View in: PubMed
    Score: 0.173
  9. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clin Genitourin Cancer. 2019 02; 17(1):1-6.
    View in: PubMed
    Score: 0.164
  10. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer. 2017 Dec 15; 123(24):4823-4831.
    View in: PubMed
    Score: 0.152
  11. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017 09; 198(3):530-537.
    View in: PubMed
    Score: 0.148
  12. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. J Urol. 2016 Sep; 196(3):678-84.
    View in: PubMed
    Score: 0.138
  13. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urol Oncol. 2016 May; 34(5):237.e19-26.
    View in: PubMed
    Score: 0.135
  14. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2016 05; 69(5):866-74.
    View in: PubMed
    Score: 0.135
  15. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol. 2015 Oct; 33(10):427.e17-23.
    View in: PubMed
    Score: 0.130
  16. Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. J Urol. 2015 Aug; 194(2):316-22.
    View in: PubMed
    Score: 0.128
  17. Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mRCC) treated with sunitinib: Is mRCC curable with targeted therapy? Urol Case Rep. 2015 Mar 01; 3(2):18-20.
    View in: PubMed
    Score: 0.128
  18. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urol Oncol. 2015 Apr; 33(4):166.e21-9.
    View in: PubMed
    Score: 0.128
  19. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Urol. 2014 Jul; 192(1):36-42.
    View in: PubMed
    Score: 0.119
  20. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol. 2014 Nov; 66(5):874-80.
    View in: PubMed
    Score: 0.119
  21. Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU Int. 2013 May; 111(6):997-1005.
    View in: PubMed
    Score: 0.112
  22. Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma. J Urol. 2010 Nov; 184(5):1882-7.
    View in: PubMed
    Score: 0.094
  23. Clinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 Patients. Eur Urol Oncol. 2024 Jul 15.
    View in: PubMed
    Score: 0.061
  24. YIA24-001: Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial. J Natl Compr Canc Netw. 2024 Apr 05; 22(2.5).
    View in: PubMed
    Score: 0.060
  25. Radiation Therapy for the Management of Renal Medullary Carcinoma: A Multi-Case Study. Clin Genitourin Cancer. 2024 Jun; 22(3):102065.
    View in: PubMed
    Score: 0.060
  26. Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy. Clin Transl Med. 2023 05; 13(5):e1267.
    View in: PubMed
    Score: 0.056
  27. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus. 2023 09; 9(5):734-741.
    View in: PubMed
    Score: 0.056
  28. Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers (Basel). 2021 Nov 30; 13(23).
    View in: PubMed
    Score: 0.051
  29. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun. 2021 11 04; 12(1):6375.
    View in: PubMed
    Score: 0.051
  30. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer. 2021 12; 19(6):e401-e408.
    View in: PubMed
    Score: 0.050
  31. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int. 2022 05; 129(5):610-620.
    View in: PubMed
    Score: 0.050
  32. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers (Basel). 2021 Apr 30; 13(9).
    View in: PubMed
    Score: 0.049
  33. Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. BJU Int. 2020 12; 126(6):745-753.
    View in: PubMed
    Score: 0.047
  34. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. Cancer. 2020 09 01; 126(17):3950-3960.
    View in: PubMed
    Score: 0.046
  35. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell. 2020 05 11; 37(5):720-734.e13.
    View in: PubMed
    Score: 0.046
  36. Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. Sci Rep. 2020 01 20; 10(1):701.
    View in: PubMed
    Score: 0.045
  37. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol. 2019 11; 32(11):1698-1707.
    View in: PubMed
    Score: 0.043
  38. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell. 2019 02 11; 35(2):204-220.e9.
    View in: PubMed
    Score: 0.042
  39. Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence. Am J Pathol. 2018 11; 188(11):2487-2496.
    View in: PubMed
    Score: 0.041
  40. Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome. Carcinogenesis. 2018 05 28; 39(6):752-757.
    View in: PubMed
    Score: 0.040
  41. Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. Clin Cancer Res. 2017 Nov 01; 23(21):6686-6696.
    View in: PubMed
    Score: 0.038
  42. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma. Cancer. 2017 Sep 15; 123(18):3617-3627.
    View in: PubMed
    Score: 0.037
  43. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer. 2017 06; 15(3):363-370.
    View in: PubMed
    Score: 0.037
  44. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017 12; 120(6):782-792.
    View in: PubMed
    Score: 0.036
  45. DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. Clin Cancer Res. 2016 Dec 15; 22(24):6236-6246.
    View in: PubMed
    Score: 0.035
  46. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. Eur Urol. 2016 08; 70(2):348-57.
    View in: PubMed
    Score: 0.034
  47. Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case-Control Study. Clin Cancer Res. 2016 Apr 15; 22(8):2074-82.
    View in: PubMed
    Score: 0.034
  48. Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in the etiology of renal cell carcinoma. Cancer. 2016 Jan 01; 122(1):108-15.
    View in: PubMed
    Score: 0.034
  49. Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. J Pathol Clin Res. 2015 Oct; 1(4):212-24.
    View in: PubMed
    Score: 0.033
  50. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016 May; 117(5):761-5.
    View in: PubMed
    Score: 0.033
  51. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol. 2015 Sep; 28(9):1225-35.
    View in: PubMed
    Score: 0.033
  52. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2015 Sep; 3(9):1017-29.
    View in: PubMed
    Score: 0.033
  53. Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. Eur Urol. 2013 Jun; 63(6):1122-7.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.